(CRBN) Corbion - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0010583399
Stock: Lactic Acid, Food Preservatives, Algae Ingredients, Bioplastics, Biochemicals
Total Rating 49
Risk 96
Buy Signal 0.77
Dividends
| Dividend Yield | 3.36% |
| Yield on Cost 5y | 1.34% |
| Yield CAGR 5y | 3.39% |
| Payout Consistency | 89.5% |
| Payout Ratio | 87.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.6% |
| Relative Tail Risk | -19.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.17 |
| Alpha | -10.36 |
| Character TTM | |
|---|---|
| Beta | 0.231 |
| Beta Downside | 0.299 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.60% |
| CAGR/Max DD | -0.25 |
Description: CRBN Corbion January 19, 2026
Corbion N.V. (AS: CRBN) is a Dutch specialty-chemicals group that manufactures lactic-acid-based ingredients, food-preservation solutions, functional blends, and algae-derived oils. Its operations are split between the Functional Ingredients & Solutions segment and the Health & Nutrition segment, serving food, personal-care, animal-nutrition, pharmaceutical, medical-device and bioplastic markets through a global network of sales offices and distributors.
Key metrics (FY 2023) show revenue of roughly €1.1 billion with an adjusted EBITDA margin near 12 %, while sales of its biodegradable bioplastics rose ~20 % year-on-year. The lactic-acid market is expanding at a 5-6 % CAGR, driven by EU Green-Deal policies that incentivise low-carbon, renewable feedstocks, and the company’s recent partnership with BRAIN Biotech AG to co-develop novel biobased antimicrobials could unlock additional high-margin growth.
For a deeper, data-rich assessment of Corbion’s valuation and risk profile, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 141.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 19.39 > 1.0 |
| NWC/Revenue: 3.44% < 20% (prev 1.37%; Δ 2.07% < -1%) |
| CFO/TA 0.24 > 3% & CFO 343.8m > Net Income 141.6m |
| Net Debt (454.2m) to EBITDA (395.2m): 1.15 < 3 |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago -1.50% < -2% |
| Gross Margin: 25.43% > 18% (prev 0.23%; Δ 2520 % > 0.5%) |
| Asset Turnover: 166.2% > 50% (prev 87.54%; Δ 78.64% > 0%) |
| Interest Coverage Ratio: 3.84 > 6 (EBITDA TTM 395.2m / Interest Expense TTM 57.7m) |
Altman Z'' 3.85
| A: 0.06 (Total Current Assets 514.2m - Total Current Liabilities 423.3m) / Total Assets 1.45b |
| B: 0.47 (Retained Earnings 685.1m / Total Assets 1.45b) |
| C: 0.14 (EBIT TTM 221.6m / Avg Total Assets 1.59b) |
| D: 0.92 (Book Value of Equity 671.0m / Total Liabilities 727.3m) |
| Altman-Z'' Score: 3.85 = AA |
Beneish M -3.27
| DSRI: 0.42 (Receivables 208.4m/281.4m, Revenue 2.64b/1.51b) |
| GMI: 0.89 (GM 25.43% / 22.60%) |
| AQI: 0.90 (AQ_t 0.16 / AQ_t-1 0.18) |
| SGI: 1.75 (Revenue 2.64b / 1.51b) |
| TATA: -0.14 (NI 141.6m - CFO 343.8m) / TA 1.45b) |
| Beneish M-Score: -3.27 (Cap -4..+1) = AA |
What is the price of CRBN shares?
As of February 08, 2026, the stock is trading at EUR 21.02 with a total of 94,187 shares traded.
Over the past week, the price has changed by +3.85%, over one month by +12.83%, over three months by +19.36% and over the past year by -2.82%.
Over the past week, the price has changed by +3.85%, over one month by +12.83%, over three months by +19.36% and over the past year by -2.82%.
Is CRBN a buy, sell or hold?
Corbion has no consensus analysts rating.
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.6 | 17% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21.5 | 2.2% |
CRBN Fundamental Data Overview February 03, 2026
Market Cap USD = 1.40b (1.19b EUR * 1.1801 EUR.USD)
P/E Trailing = 18.4504
P/E Forward = 14.0647
P/S = 0.9182
P/B = 1.5827
Revenue TTM = 2.64b EUR
EBIT TTM = 221.6m EUR
EBITDA TTM = 395.2m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 212.4m EUR (from shortTermDebt, last quarter)
Debt = 494.3m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 454.2m EUR (from netDebt column, last quarter)
Enterprise Value = 1.64b EUR (1.19b + Debt 494.3m - CCE 40.1m)
Interest Coverage Ratio = 3.84 (Ebit TTM 221.6m / Interest Expense TTM 57.7m)
EV/FCF = 9.63x (Enterprise Value 1.64b / FCF TTM 170.8m)
FCF Yield = 10.38% (FCF TTM 170.8m / Enterprise Value 1.64b)
FCF Margin = 6.47% (FCF TTM 170.8m / Revenue TTM 2.64b)
Net Margin = 5.36% (Net Income TTM 141.6m / Revenue TTM 2.64b)
Gross Margin = 25.43% ((Revenue TTM 2.64b - Cost of Revenue TTM 1.97b) / Revenue TTM)
Gross Margin QoQ = 27.14% (prev 24.44%)
Tobins Q-Ratio = 1.13 (Enterprise Value 1.64b / Total Assets 1.45b)
Interest Expense / Debt = 2.65% (Interest Expense 13.1m / Debt 494.3m)
Taxrate = 17.99% (9.30m / 51.7m)
NOPAT = 181.7m (EBIT 221.6m * (1 - 17.99%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.68 (Debt 494.3m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.15 (Net Debt 454.2m / EBITDA 395.2m)
Debt / FCF = 2.66 (Net Debt 454.2m / FCF TTM 170.8m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.91% (Net Income 141.6m / Total Assets 1.45b)
RoE = 19.58% (Net Income TTM 141.6m / Total Stockholder Equity 723.2m)
RoCE = 22.89% (EBIT 221.6m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 14.68% (NOPAT 181.7m / Invested Capital 1.24b)
WACC = 5.42% (E(1.19b)/V(1.68b) * Re(6.77%) + D(494.3m)/V(1.68b) * Rd(2.65%) * (1-Tc(0.18)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈170.8m ; Y1≈112.1m ; Y5≈51.2m
Fair Price DCF = 20.43 (EV 1.63b - Net Debt 454.2m = Equity 1.18b / Shares 57.6m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 65.60 | Revenue CAGR: 10.20% | SUE: 0.81 | # QB: 0
EPS next Year (2026-12-31): EPS=1.47 | Chg30d=+0.018 | Revisions Net=+0 | Growth EPS=+11.0% | Growth Revenue=+1.9%
P/E Trailing = 18.4504
P/E Forward = 14.0647
P/S = 0.9182
P/B = 1.5827
Revenue TTM = 2.64b EUR
EBIT TTM = 221.6m EUR
EBITDA TTM = 395.2m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 212.4m EUR (from shortTermDebt, last quarter)
Debt = 494.3m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 454.2m EUR (from netDebt column, last quarter)
Enterprise Value = 1.64b EUR (1.19b + Debt 494.3m - CCE 40.1m)
Interest Coverage Ratio = 3.84 (Ebit TTM 221.6m / Interest Expense TTM 57.7m)
EV/FCF = 9.63x (Enterprise Value 1.64b / FCF TTM 170.8m)
FCF Yield = 10.38% (FCF TTM 170.8m / Enterprise Value 1.64b)
FCF Margin = 6.47% (FCF TTM 170.8m / Revenue TTM 2.64b)
Net Margin = 5.36% (Net Income TTM 141.6m / Revenue TTM 2.64b)
Gross Margin = 25.43% ((Revenue TTM 2.64b - Cost of Revenue TTM 1.97b) / Revenue TTM)
Gross Margin QoQ = 27.14% (prev 24.44%)
Tobins Q-Ratio = 1.13 (Enterprise Value 1.64b / Total Assets 1.45b)
Interest Expense / Debt = 2.65% (Interest Expense 13.1m / Debt 494.3m)
Taxrate = 17.99% (9.30m / 51.7m)
NOPAT = 181.7m (EBIT 221.6m * (1 - 17.99%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.68 (Debt 494.3m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.15 (Net Debt 454.2m / EBITDA 395.2m)
Debt / FCF = 2.66 (Net Debt 454.2m / FCF TTM 170.8m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.91% (Net Income 141.6m / Total Assets 1.45b)
RoE = 19.58% (Net Income TTM 141.6m / Total Stockholder Equity 723.2m)
RoCE = 22.89% (EBIT 221.6m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 14.68% (NOPAT 181.7m / Invested Capital 1.24b)
WACC = 5.42% (E(1.19b)/V(1.68b) * Re(6.77%) + D(494.3m)/V(1.68b) * Rd(2.65%) * (1-Tc(0.18)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈170.8m ; Y1≈112.1m ; Y5≈51.2m
Fair Price DCF = 20.43 (EV 1.63b - Net Debt 454.2m = Equity 1.18b / Shares 57.6m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 65.60 | Revenue CAGR: 10.20% | SUE: 0.81 | # QB: 0
EPS next Year (2026-12-31): EPS=1.47 | Chg30d=+0.018 | Revisions Net=+0 | Growth EPS=+11.0% | Growth Revenue=+1.9%